1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic

 
• By Joseph Haas, Beth Allan, Deanna Kamienski, and Maureen Riordan

Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.

Tech Transfer regular column feature image

Continuing a collaborative research agreement signed in 2016, Neon Therapeutics licensed technology from the [Netherlands Cancer Institute] (NKI) that will enable it to advance its personalized neoantigen T-cell therapy candidate NEO-PTC-01 into clinical development.

The agreement announced Oct. 4 grants the Cambridge, Mass.-based biotech exclusive intellectual property rights for an ex vivo induction platform developed in collaboration by NKI researchers John Haanen and Joost van den Berg and Neon’s co-founder Ton Schumacher

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Business

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.